KYPROLIS
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
Final ANDA candidate 209330/001 on 2021-06-11. Source-level RLD/TE screen; earliest Final and exact Product source reference require independent review.
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| 7417042 | 2026-07-20 | DS/DP — | — | — | — | — | — | — |
| 7417042 | 2027-01-20 | — — | — | — | — | — | 2027-01-20 | — |
| 7737112 | 2027-12-07 | DP — | — | — | — | — | — | — |
| 7737112 | 2028-06-07 | — — | — | — | — | — | 2028-06-07 | — |
| RE47954 | 2029-10-21 | U U-3449 | — | — | — | — | — | — |
| RE47954 | 2030-04-21 | — — | — | — | — | — | 2030-04-21 | — |
| 9493582 | 2033-02-27 | DP — | — | — | — | — | — | — |
| 9493582 | 2033-08-27 | — — | — | — | — | — | 2033-08-27 | — |
| 12636340 | 2041-04-29 | U U-4551 | — | — | — | — | — | — |
| 12636340 | 2041-10-29 | — — | — | — | — | — | 2041-10-29 | — |
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| M-14 | — | 2028-05-22 | — | — | — | — | Source | |
| PED | — | 2028-11-22 | — | — | — | — | Source |
2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| 209330 / 001 | FINAL_APPROVAL · FINAL_APPROVED | 2021-06-11 | — | BRECKENRIDGE PHARMACEUTICAL INC | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 0 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No authorized-generic records are linked to this product. | ||||||
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 1 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| 209330 / 001 | BRECKENRIDGE PHARMACEUTICAL INC | FINAL_APPROVAL · FINAL_APPROVED | 2021-06-11 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
| Event date | Party | Event | Licensed entry | Evidence | Source |
|---|---|---|---|---|---|
| 2019-05-30 | Onyx Therapeutics, Inc. / NATCO Pharma Limited / Breckenridge Pharmaceutical, Inc. | SETTLEMENT Brand-level record; strength scope not established
|
2027 | SOURCE_CONFIRMED | Source |
| 2019-05-30 is the public settlement announcement date, not necessarily the confidential contract signature date. NATCO, Breckenridge and Onyx settled Paragraph IV patent litigation concerning KYPROLIS (carfilzomib) 10mg, 30mg and 60mg. District Court case dismissed. NATCO/Breckenridge licensed to launch on a CONFIDENTIAL day in 2027, potentially earlier if specified conditions occur. This is not a verified commercial launch or a definite mid-2027 date. License applies only to named parties; do not treat all generic applicants as licensed. 2021 Breckenridge company disclosure: its 10mg and 60mg ANDA strengths final approved, 30mg tentative at that time. Distinguish from separate 2019 first final ANDA. 2019 announcement: https://firstwordpharma.com/story/4798731 | |||||